Free tool
FAERS Monitor: Inlyta
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 202324 or its brand name (Inlyta, Axitinib). Reports on generic versions are filed under their own applications.
Reports
19,549
Serious
12,971
66% of reports
Hospitalization
5,052
Death reported
3,948
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death2,699
- diarrhoea2,594
- fatigue2,123
- hypertension1,331
- neoplasm progression1,324
- disease progression1,211
- off label use1,207
- nausea1,145
- decreased appetite1,094
- dysphonia1,013
- blood pressure increased855
- weight decreased806
- asthenia765
- headache604
- stomatitis594
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2008 | 1 |
| 2009 | 18 |
| 2010 | 32 |
| 2011 | 28 |
| 2012 | 569 |
| 2013 | 1,060 |
| 2014 | 1,157 |
| 2015 | 1,094 |
| 2016 | 814 |
| 2017 | 766 |
| 2018 | 697 |
| 2019 | 1,160 |
| 2020 | 2,413 |
| 2021 | 2,270 |
| 2022 | 2,688 |
| 2023 | 1,907 |
| 2024 | 1,429 |
| 2025 | 889 |
| 2026 | 557 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,034,610 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| neoplasm progressionSignal | 1,324 | 42.6 | 40.4 | 51,732 |
| dysphoniaSignal | 1,013 | 18.9 | 17.8 | 16,949 |
| disease progressionSignal | 1,211 | 11.1 | 10.5 | 11,085 |
| stomatitisSignal | 594 | 10.6 | 9.8 | 5,137 |
| hypertensionSignal | 1,331 | 6.8 | 6.5 | 6,601 |
| blood pressure increasedSignal | 855 | 6.0 | 5.7 | 3,601 |
| decreased appetiteSignal | 1,094 | 5.1 | 4.8 | 3,611 |
| diarrhoeaSignal | 2,594 | 4.3 | 4.2 | 6,840 |
| deathSignal | 2,699 | 3.4 | 3.3 | 4,694 |
| weight decreasedSignal | 806 | 3.1 | 2.9 | 1,166 |
| fatigueSignal | 2,123 | 2.9 | 2.8 | 2,811 |
| astheniaSignal | 765 | 2.2 | 2.0 | 502 |
| nausea | 1,145 | 1.6 | 1.5 | 236 |
| off label use | 1,207 | 1.5 | 1.4 | 198 |
| headache | 604 | 1.0 | 1.0 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.